PT2725908T - Compostos opioides de ação periférica - Google Patents

Info

Publication number

PT2725908T

PT2725908T PT128050879T PT12805087T PT2725908T PT 2725908 T PT2725908 T PT 2725908T PT 128050879 T PT128050879 T PT 128050879T PT 12805087 T PT12805087 T PT 12805087T PT 2725908 T PT2725908 T PT 2725908T

Authority

PT

Portugal

Prior art keywords

substituted

pain

compound

neuralgia

aryl

Prior art date

2011-06-29

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 151
• 239000000203 mixture Substances 0.000 claims description 46
• 208000002193 Pain Diseases 0.000 claims description 45
• 125000000623 heterocyclic group Chemical group 0.000 claims description 41
• 238000000034 method Methods 0.000 claims description 37
• 125000001931 aliphatic group Chemical group 0.000 claims description 32
• 125000003118 aryl group Chemical group 0.000 claims description 32
• 230000036407 pain Effects 0.000 claims description 31
• 125000000217 alkyl group Chemical group 0.000 claims description 26
• 239000001257 hydrogen Substances 0.000 claims description 26
• 229910052739 hydrogen Inorganic materials 0.000 claims description 26
• 208000004296 neuralgia Diseases 0.000 claims description 25
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
• 125000003107 substituted aryl group Chemical group 0.000 claims description 20
• 125000003282 alkyl amino group Chemical group 0.000 claims description 18
• 230000000694 effects Effects 0.000 claims description 16
• 201000010099 disease Diseases 0.000 claims description 15
• 150000002431 hydrogen Chemical class 0.000 claims description 15
• 206010029240 Neuritis Diseases 0.000 claims description 14
• 125000004414 alkyl thio group Chemical group 0.000 claims description 14
• 230000001404 mediated effect Effects 0.000 claims description 13
• 125000002252 acyl group Chemical group 0.000 claims description 12
• 125000003342 alkenyl group Chemical group 0.000 claims description 12
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
• 125000001424 substituent group Chemical group 0.000 claims description 12
• 150000002148 esters Chemical class 0.000 claims description 11
• 208000003251 Pruritus Diseases 0.000 claims description 10
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 10
• 125000001072 heteroaryl group Chemical group 0.000 claims description 10
• 208000019695 Migraine disease Diseases 0.000 claims description 9
• 229910052736 halogen Inorganic materials 0.000 claims description 9
• 150000002367 halogens Chemical class 0.000 claims description 9
• 206010027599 migraine Diseases 0.000 claims description 9
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
• 208000000094 Chronic Pain Diseases 0.000 claims description 8
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
• 125000003545 alkoxy group Chemical group 0.000 claims description 8
• 125000000304 alkynyl group Chemical group 0.000 claims description 8
• 206010013663 drug dependence Diseases 0.000 claims description 8
• 230000004064 dysfunction Effects 0.000 claims description 8
• 208000007848 Alcoholism Diseases 0.000 claims description 7
• 206010065390 Inflammatory pain Diseases 0.000 claims description 7
• 201000007930 alcohol dependence Diseases 0.000 claims description 7
• 229910052799 carbon Inorganic materials 0.000 claims description 7
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
• 208000035475 disorder Diseases 0.000 claims description 7
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
• 229910052760 oxygen Inorganic materials 0.000 claims description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 7
• 206010012735 Diarrhoea Diseases 0.000 claims description 6
• 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 6
• 206010038678 Respiratory depression Diseases 0.000 claims description 6
• 208000005298 acute pain Diseases 0.000 claims description 6
• 208000021722 neuropathic pain Diseases 0.000 claims description 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
• 229910052717 sulfur Inorganic materials 0.000 claims description 6
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
• 206010011224 Cough Diseases 0.000 claims description 5
• 201000004624 Dermatitis Diseases 0.000 claims description 5
• 208000004454 Hyperalgesia Diseases 0.000 claims description 5
• 208000035154 Hyperesthesia Diseases 0.000 claims description 5
• 208000008589 Obesity Diseases 0.000 claims description 5
• 208000026251 Opioid-Related disease Diseases 0.000 claims description 5
• 206010054048 Postoperative ileus Diseases 0.000 claims description 5
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
• 206010003246 arthritis Diseases 0.000 claims description 5
• 235000020824 obesity Nutrition 0.000 claims description 5
• 201000005040 opiate dependence Diseases 0.000 claims description 5
• 208000011117 substance-related disease Diseases 0.000 claims description 5
• 125000005415 substituted alkoxy group Chemical group 0.000 claims description 5
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
• 206010010904 Convulsion Diseases 0.000 claims description 4
• 206010019233 Headaches Diseases 0.000 claims description 4
• 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 4
• 206010029279 Neurogenic bladder Diseases 0.000 claims description 4
• 206010047700 Vomiting Diseases 0.000 claims description 4
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
• 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
• 231100000869 headache Toxicity 0.000 claims description 4
• 201000008482 osteoarthritis Diseases 0.000 claims description 4
• 239000001301 oxygen Substances 0.000 claims description 4
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
• 208000022497 Cocaine-Related disease Diseases 0.000 claims description 3
• 206010010774 Constipation Diseases 0.000 claims description 3
• 208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
• 206010028980 Neoplasm Diseases 0.000 claims description 3
• 206010057852 Nicotine dependence Diseases 0.000 claims description 3
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
• 208000025569 Tobacco Use disease Diseases 0.000 claims description 3
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
• 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 3
• 125000005122 aminoalkylamino group Chemical group 0.000 claims description 3
• 125000005128 aryl amino alkyl group Chemical group 0.000 claims description 3
• 125000001769 aryl amino group Chemical group 0.000 claims description 3
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 3
• 208000010668 atopic eczema Diseases 0.000 claims description 3
• 201000011510 cancer Diseases 0.000 claims description 3
• 150000001721 carbon Chemical group 0.000 claims description 3
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
• 201000006145 cocaine dependence Diseases 0.000 claims description 3
• 230000005176 gastrointestinal motility Effects 0.000 claims description 3
• 125000001188 haloalkyl group Chemical group 0.000 claims description 3
• 208000008384 ileus Diseases 0.000 claims description 3
• 208000014674 injury Diseases 0.000 claims description 3
• 230000002981 neuropathic effect Effects 0.000 claims description 3
• 238000006467 substitution reaction Methods 0.000 claims description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
• 208000011580 syndromic disease Diseases 0.000 claims description 3
• 230000008733 trauma Effects 0.000 claims description 3
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
• 206010003399 Arthropod bite Diseases 0.000 claims description 2
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
• 201000006390 Brachial Plexus Neuritis Diseases 0.000 claims description 2
• 206010068065 Burning mouth syndrome Diseases 0.000 claims description 2
• 206010058019 Cancer Pain Diseases 0.000 claims description 2
• 208000001387 Causalgia Diseases 0.000 claims description 2
• 206010007882 Cellulitis Diseases 0.000 claims description 2
• 208000006561 Cluster Headache Diseases 0.000 claims description 2
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 2
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
• 208000005171 Dysmenorrhea Diseases 0.000 claims description 2
• 208000004232 Enteritis Diseases 0.000 claims description 2
• 208000001640 Fibromyalgia Diseases 0.000 claims description 2
• 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims description 2
• 201000005569 Gout Diseases 0.000 claims description 2
• 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
• 206010063491 Herpes zoster oticus Diseases 0.000 claims description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
• 206010049949 Intercostal neuralgia Diseases 0.000 claims description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
• 208000002472 Morton Neuroma Diseases 0.000 claims description 2
• 208000020059 Morton neuralgia Diseases 0.000 claims description 2
• 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
• 201000010927 Mucositis Diseases 0.000 claims description 2
• 206010068106 Occipital neuralgia Diseases 0.000 claims description 2
• 208000003435 Optic Neuritis Diseases 0.000 claims description 2
• 206010034464 Periarthritis Diseases 0.000 claims description 2
• 201000007100 Pharyngitis Diseases 0.000 claims description 2
• 206010036105 Polyneuropathy Diseases 0.000 claims description 2
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 2
• 206010040744 Sinus headache Diseases 0.000 claims description 2
• 208000004078 Snake Bites Diseases 0.000 claims description 2
• 208000026137 Soft tissue injury Diseases 0.000 claims description 2
• 206010054874 Sphenopalatine neuralgia Diseases 0.000 claims description 2
• 208000003589 Spider Bites Diseases 0.000 claims description 2
• 206010042496 Sunburn Diseases 0.000 claims description 2
• 206010043269 Tension headache Diseases 0.000 claims description 2
• 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
• 230000009692 acute damage Effects 0.000 claims description 2
• 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 2
• 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims description 2
• 230000002146 bilateral effect Effects 0.000 claims description 2
• 125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
• 201000001352 cholecystitis Diseases 0.000 claims description 2
• 208000018912 cluster headache syndrome Diseases 0.000 claims description 2
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 2
• 208000010247 contact dermatitis Diseases 0.000 claims description 2
• 208000012790 cranial neuralgia Diseases 0.000 claims description 2
• 230000002496 gastric effect Effects 0.000 claims description 2
• 201000011349 geniculate herpes zoster Diseases 0.000 claims description 2
• 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims description 2
• 230000000968 intestinal effect Effects 0.000 claims description 2
• 208000037805 labour Diseases 0.000 claims description 2
• 230000001617 migratory effect Effects 0.000 claims description 2
• 201000001119 neuropathy Diseases 0.000 claims description 2
• 208000019629 polyneuritis Diseases 0.000 claims description 2
• 208000037821 progressive disease Diseases 0.000 claims description 2
• 206010039083 rhinitis Diseases 0.000 claims description 2
• 208000007771 sciatic neuropathy Diseases 0.000 claims description 2
• 238000001356 surgical procedure Methods 0.000 claims description 2
• 208000004371 toothache Diseases 0.000 claims description 2
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
• 208000009935 visceral pain Diseases 0.000 claims description 2
• 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 1
• MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 claims 1
• 206010028813 Nausea Diseases 0.000 claims 1
• 208000004967 femoral neuropathy Diseases 0.000 claims 1
• 125000001475 halogen functional group Chemical group 0.000 claims 1
• 208000032184 meralgia paresthetica Diseases 0.000 claims 1
• 230000008693 nausea Effects 0.000 claims 1
• 201000009985 neuronitis Diseases 0.000 claims 1
• 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
• 230000008673 vomiting Effects 0.000 claims 1
• -1 -N3 Chemical group 0.000 description 128
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 95
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 57
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 41
• 125000004432 carbon atom Chemical group C* 0.000 description 36
• 238000011282 treatment Methods 0.000 description 36
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 28
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
• 238000012360 testing method Methods 0.000 description 26
• 150000003254 radicals Chemical class 0.000 description 25
• 239000011541 reaction mixture Substances 0.000 description 25
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
• 230000002829 reductive effect Effects 0.000 description 24
• 239000007787 solid Substances 0.000 description 24
• 238000006243 chemical reaction Methods 0.000 description 23
• 239000000243 solution Substances 0.000 description 23
• 239000002904 solvent Substances 0.000 description 22
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
• 238000003786 synthesis reaction Methods 0.000 description 21
• 229960005181 morphine Drugs 0.000 description 20
• 102000003840 Opioid Receptors Human genes 0.000 description 19
• 108090000137 Opioid Receptors Proteins 0.000 description 19
• 230000027455 binding Effects 0.000 description 18
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
• 230000015572 biosynthetic process Effects 0.000 description 17
• 239000003814 drug Substances 0.000 description 17
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
• 229940079593 drug Drugs 0.000 description 16
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
• 239000012071 phase Substances 0.000 description 14
• 150000003839 salts Chemical class 0.000 description 13
• 241001465754 Metazoa Species 0.000 description 12
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 12
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
• 235000019341 magnesium sulphate Nutrition 0.000 description 12
• 238000007920 subcutaneous administration Methods 0.000 description 12
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
• 229920006395 saturated elastomer Polymers 0.000 description 11
• 241000699670 Mus sp. Species 0.000 description 10
• 241000700159 Rattus Species 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 231100000673 dose–response relationship Toxicity 0.000 description 10
• 239000003921 oil Substances 0.000 description 10
• 235000019198 oils Nutrition 0.000 description 10
• 230000002093 peripheral effect Effects 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 239000003981 vehicle Substances 0.000 description 10
• 230000003502 anti-nociceptive effect Effects 0.000 description 9
• 125000000753 cycloalkyl group Chemical group 0.000 description 9
• 125000004433 nitrogen atom Chemical group N* 0.000 description 9
• 239000012074 organic phase Substances 0.000 description 9
• 229940002612 prodrug Drugs 0.000 description 9
• 239000000651 prodrug Substances 0.000 description 9
• 230000000202 analgesic effect Effects 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 238000001914 filtration Methods 0.000 description 8
• 125000002911 monocyclic heterocycle group Chemical group 0.000 description 8
• 229940005483 opioid analgesics Drugs 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
• 238000004440 column chromatography Methods 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 102000051367 mu Opioid Receptors Human genes 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• 239000000377 silicon dioxide Substances 0.000 description 7
• 108020001612 μ-opioid receptors Proteins 0.000 description 7
• MMCDLAMVXLIFCA-KVXGTOJUSA-N 4,14-dihydroxy-n-{2-[4-(2-methoxypyrimidin-5-yl)phenyl]ethyl}-17-methyl-6-oxomorphinan-3-carboxamide Chemical compound C([C@]1(N(CC[C@@]2(C3=C4O)[C@]1(CCC(=O)C2)O)C)[H])C3=CC=C4C(=O)NCCC(C=C1)=CC=C1C1=CN=C(OC)N=C1 MMCDLAMVXLIFCA-KVXGTOJUSA-N 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 230000036592 analgesia Effects 0.000 description 6
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
• 238000007912 intraperitoneal administration Methods 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 231100000252 nontoxic Toxicity 0.000 description 6
• 230000003000 nontoxic effect Effects 0.000 description 6
• 239000012044 organic layer Substances 0.000 description 6
• 125000004430 oxygen atom Chemical group O* 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 125000005164 aryl thioalkyl group Chemical group 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 239000012043 crude product Substances 0.000 description 5
• 230000002354 daily effect Effects 0.000 description 5
• 230000006735 deficit Effects 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 235000019441 ethanol Nutrition 0.000 description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 239000008101 lactose Substances 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 230000033001 locomotion Effects 0.000 description 5
• SLYCZBAANLHQTL-LPPUWEFUSA-N n-[2-(4-bromophenyl)ethyl]-4,14-dihydroxy-17-methyl-6-oxomorphinan-3-carboxamide Chemical compound C([C@]1(N(CC[C@@]2(C3=C4O)[C@]1(CCC(=O)C2)O)C)[H])C3=CC=C4C(=O)NCCC1=CC=C(Br)C=C1 SLYCZBAANLHQTL-LPPUWEFUSA-N 0.000 description 5
• UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 5
• 229960004127 naloxone Drugs 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 229910000029 sodium carbonate Inorganic materials 0.000 description 5
• 125000004434 sulfur atom Chemical group 0.000 description 5
• MRQBIMZMDWOQLF-UHFFFAOYSA-N tert-butyl n-[2-(4-bromophenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=CC=C(Br)C=C1 MRQBIMZMDWOQLF-UHFFFAOYSA-N 0.000 description 5
• MSTIRKRGPZOHSY-UHFFFAOYSA-N tert-butyl n-[2-[4-(6-oxo-1h-pyridin-3-yl)phenyl]ethyl]carbamate Chemical compound C1=CC(CCNC(=O)OC(C)(C)C)=CC=C1C1=CNC(=O)C=C1 MSTIRKRGPZOHSY-UHFFFAOYSA-N 0.000 description 5
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 5
• 239000001993 wax Substances 0.000 description 5
• 108020001588 κ-opioid receptors Proteins 0.000 description 5
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• WIYUZYBFCWCCQJ-IFKAHUTRSA-N Naltrindole Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3NC=25)O)CC1)O)CC1CC1 WIYUZYBFCWCCQJ-IFKAHUTRSA-N 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
• 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 235000010443 alginic acid Nutrition 0.000 description 4
• 229920000615 alginic acid Polymers 0.000 description 4
• 125000002947 alkylene group Chemical group 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 239000008346 aqueous phase Substances 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 239000012298 atmosphere Substances 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 108700023159 delta Opioid Receptors Proteins 0.000 description 4
• 102000048124 delta Opioid Receptors Human genes 0.000 description 4
• 210000002683 foot Anatomy 0.000 description 4
• 150000002430 hydrocarbons Chemical group 0.000 description 4
• 239000003701 inert diluent Substances 0.000 description 4
• 102000048260 kappa Opioid Receptors Human genes 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
• 235000021317 phosphate Nutrition 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 239000007909 solid dosage form Substances 0.000 description 4
• 239000007921 spray Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
• CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
• JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
• GDLZEGOWBYOWAG-UHFFFAOYSA-N 5-[4-(2-aminoethyl)phenyl]-1h-pyrimidine-2,4-dione;hydrochloride Chemical compound Cl.C1=CC(CCN)=CC=C1C1=CNC(=O)NC1=O GDLZEGOWBYOWAG-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 206010002091 Anaesthesia Diseases 0.000 description 3
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
• 208000012661 Dyskinesia Diseases 0.000 description 3
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 125000004450 alkenylene group Chemical group 0.000 description 3
• 125000004419 alkynylene group Chemical group 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 229910021529 ammonia Inorganic materials 0.000 description 3
• 239000000908 ammonium hydroxide Substances 0.000 description 3
• 230000037005 anaesthesia Effects 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 239000001961 anticonvulsive agent Substances 0.000 description 3
• 125000003710 aryl alkyl group Chemical group 0.000 description 3
• 125000004104 aryloxy group Chemical group 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
• 239000006172 buffering agent Substances 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 229940126543 compound 14 Drugs 0.000 description 3
• 125000000392 cycloalkenyl group Chemical group 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 229940075894 denatured ethanol Drugs 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical compound C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 239000003960 organic solvent Substances 0.000 description 3
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000004224 protection Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 239000002287 radioligand Substances 0.000 description 3
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• KMRBJMRLFOGAKI-UHFFFAOYSA-N tert-butyl n-[2-[4-(2,4-dimethoxypyrimidin-5-yl)phenyl]ethyl]carbamate Chemical compound COC1=NC(OC)=NC=C1C1=CC=C(CCNC(=O)OC(C)(C)C)C=C1 KMRBJMRLFOGAKI-UHFFFAOYSA-N 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• LDVUYNCUMGEBCI-HGLPBTONSA-N (1R,9R,10S)-3,10-dihydroxy-17-methyl-13-oxo-N-[2-[4-(2-oxo-1H-pyrimidin-5-yl)phenyl]ethyl]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4-carboxamide Chemical compound C([C@@H]1[C@]2(O)CCC(=O)C[C@@]2(C2=C3O)CCN1C)C2=CC=C3C(=O)NCCC(C=C1)=CC=C1C=1C=NC(=O)NC=1 LDVUYNCUMGEBCI-HGLPBTONSA-N 0.000 description 2
• LKGKUACPLXCVOF-UHFFFAOYSA-N (2,4-dimethoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C(OC)=N1 LKGKUACPLXCVOF-UHFFFAOYSA-N 0.000 description 2
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
• NDHIGBQXQCVRAU-QLBRKBSLSA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-(2-phenylethyl)-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CCC1=CC=CC=C1 NDHIGBQXQCVRAU-QLBRKBSLSA-N 0.000 description 2
• HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 2
• DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• LQLOZXOLHPXWSM-UHFFFAOYSA-N 2-[4-(1-benzylpyrazol-4-yl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C1=CC(CCN)=CC=C1C1=CN(CC=2C=CC=CC=2)N=C1 LQLOZXOLHPXWSM-UHFFFAOYSA-N 0.000 description 2
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 208000003870 Drug Overdose Diseases 0.000 description 2
• 241000400611 Eucalyptus deanei Species 0.000 description 2
• RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 235000019502 Orange oil Nutrition 0.000 description 2
• 206010033296 Overdoses Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 208000004880 Polyuria Diseases 0.000 description 2
• 206010037423 Pulmonary oedema Diseases 0.000 description 2
• 206010039897 Sedation Diseases 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 206010046543 Urinary incontinence Diseases 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
• WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
• 125000004103 aminoalkyl group Chemical group 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 230000000954 anitussive effect Effects 0.000 description 2
• 239000000730 antalgic agent Substances 0.000 description 2
• 229940125681 anticonvulsant agent Drugs 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000003434 antitussive agent Substances 0.000 description 2
• 229940124584 antitussives Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000000010 aprotic solvent Substances 0.000 description 2
• 230000003542 behavioural effect Effects 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 239000012267 brine Substances 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
• 235000019437 butane-1,3-diol Nutrition 0.000 description 2
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 230000005961 cardioprotection Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 230000001149 cognitive effect Effects 0.000 description 2
• 229940125758 compound 15 Drugs 0.000 description 2
• 235000012343 cottonseed oil Nutrition 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 2
• 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 230000035619 diuresis Effects 0.000 description 2
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
• 229940043264 dodecyl sulfate Drugs 0.000 description 2
• 231100000725 drug overdose Toxicity 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 210000000548 hind-foot Anatomy 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 2
• 229960002240 iloprost Drugs 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000007794 irritation Effects 0.000 description 2
• 229960002725 isoflurane Drugs 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 229910001629 magnesium chloride Inorganic materials 0.000 description 2
• 239000011976 maleic acid Substances 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
• 229960003086 naltrexone Drugs 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
• 229940127240 opiate Drugs 0.000 description 2
• 239000003401 opiate antagonist Substances 0.000 description 2
• 239000010502 orange oil Substances 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 239000002304 perfume Substances 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 230000000704 physical effect Effects 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 206010036596 premature ejaculation Diseases 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 208000020016 psychiatric disease Diseases 0.000 description 2
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 230000036280 sedation Effects 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 101150024821 tetO gene Proteins 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 239000003039 volatile agent Substances 0.000 description 2
• XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 2
• YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• WJRDBMPSRMAQBU-KVXGTOJUSA-N (1R,9R,10S)-3,10-dihydroxy-17-methyl-13-oxo-N-[2-[4-(2-oxo-1H-pyridin-4-yl)phenyl]ethyl]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4-carboxamide Chemical compound C([C@]1(N(CC[C@@]2(C3=C4O)[C@]1(CCC(=O)C2)O)C)[H])C3=CC=C4C(=O)NCCC(C=C1)=CC=C1C1=CC=NC(O)=C1 WJRDBMPSRMAQBU-KVXGTOJUSA-N 0.000 description 1
• YPWAJLGHACDYQS-UHFFFAOYSA-N (2-methoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C=N1 YPWAJLGHACDYQS-UHFFFAOYSA-N 0.000 description 1
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• JWDNGHGDUCLBOA-ATPOPXNDSA-N (4'r,4'as,7'ar,12'bs)-4'a-methoxy-3'-methyl-9'-phenylmethoxyspiro[1,3-dioxolane-2,7'-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline] Chemical compound C([C@@]1([C@]2(OC)CCC3([C@@H]4OC5=C6[C@@]42CCN1C)OCCO3)[H])C6=CC=C5OCC1=CC=CC=C1 JWDNGHGDUCLBOA-ATPOPXNDSA-N 0.000 description 1
• LNMPOKVQZBZVOW-JQSSMRMVSA-N (4r,4as,7ar,12bs)-n-[2-[4-(2,4-dioxo-1h-pyrimidin-5-yl)phenyl]ethyl]-4a-hydroxy-7-oxo-3-(2-phenylethyl)-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-9-carboxamide Chemical compound C([C@@]1([C@]2(O)CCC(=O)[C@@H]3OC4=C5[C@@]32CCN1CCC=1C=CC=CC=1)[H])C5=CC=C4C(=O)NCCC(C=C1)=CC=C1C1=CNC(=O)NC1=O LNMPOKVQZBZVOW-JQSSMRMVSA-N 0.000 description 1
• UOCDRBRAGVHIEA-UNBZIPRTSA-N (4r,7ar,12bs)-n-[2-[4-(2,4-dioxo-1h-pyrimidin-5-yl)phenyl]ethyl]-3-methyl-7-oxo-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-9-carboxamide Chemical compound C([C@@]1(C2CCC(=O)[C@@H]3OC4=C5[C@@]32CCN1C)[H])C5=CC=C4C(=O)NCCC(C=C1)=CC=C1C1=CNC(=O)NC1=O UOCDRBRAGVHIEA-UNBZIPRTSA-N 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
• 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• JXNAIAOHYPDQQC-UHFFFAOYSA-N 1-Benzyl-1H-pyrazole-4-boronic acid Chemical compound C1=C(B(O)O)C=NN1CC1=CC=CC=C1 JXNAIAOHYPDQQC-UHFFFAOYSA-N 0.000 description 1
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
• 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
• OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
• OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
• JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
• ZJFPQVBARDXZPX-UHFFFAOYSA-N 2,6-methano-3-benzazocine Chemical class C1=CC=C2C(C3)=CC=NC3=CC2=C1 ZJFPQVBARDXZPX-UHFFFAOYSA-N 0.000 description 1
• RNYYXSSKPYTBKH-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-1-yl)furan Chemical compound C1(CCC2=CC=CC=C12)C=1OC=CC=1 RNYYXSSKPYTBKH-UHFFFAOYSA-N 0.000 description 1
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical class CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
• BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
• IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
• NEZBDIXPIBSGOG-UHFFFAOYSA-N 4-[4-(2-aminoethyl)phenyl]-1h-pyridin-2-one;hydrochloride Chemical compound Cl.C1=CC(CCN)=CC=C1C1=CC(=O)NC=C1 NEZBDIXPIBSGOG-UHFFFAOYSA-N 0.000 description 1
• ITMFKTRAYZCBJX-UHFFFAOYSA-N 5-[4-(2-aminoethyl)phenyl]-1h-pyridin-2-one;hydrochloride Chemical compound Cl.C1=CC(CCN)=CC=C1C1=CNC(=O)C=C1 ITMFKTRAYZCBJX-UHFFFAOYSA-N 0.000 description 1
• ZVZVVDMNNBWXIV-UHFFFAOYSA-N 5-[4-(2-aminoethyl)phenyl]-1h-pyrimidine-2,4-dione Chemical compound C1=CC(CCN)=CC=C1C1=CNC(=O)NC1=O ZVZVVDMNNBWXIV-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• 206010000087 Abdominal pain upper Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 206010004663 Biliary colic Diseases 0.000 description 1
• 206010004716 Binge eating Diseases 0.000 description 1
• 206010069632 Bladder dysfunction Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 229910014585 C2-Ce Inorganic materials 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 229940126062 Compound A Drugs 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 206010011796 Cystitis interstitial Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
• 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
• 108010065372 Dynorphins Proteins 0.000 description 1
• 206010013954 Dysphoria Diseases 0.000 description 1
• 208000030814 Eating disease Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 241001539473 Euphoria Species 0.000 description 1
• 206010015535 Euphoric mood Diseases 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 239000001828 Gelatine Substances 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000836173 Homo sapiens Tumor protein p53-inducible nuclear protein 2 Proteins 0.000 description 1
• 206010021137 Hypovolaemia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010021518 Impaired gastric emptying Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000006877 Insect Bites and Stings Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 102000009151 Luteinizing Hormone Human genes 0.000 description 1
• 108010073521 Luteinizing Hormone Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
• 108090000189 Neuropeptides Proteins 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 208000007542 Paresis Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000004983 Phantom Limb Diseases 0.000 description 1
• 206010056238 Phantom pain Diseases 0.000 description 1
• 206010035039 Piloerection Diseases 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102100024622 Proenkephalin-B Human genes 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 241000862969 Stella Species 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 208000034972 Sudden Infant Death Diseases 0.000 description 1
• 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 208000009205 Tinnitus Diseases 0.000 description 1
• 206010046555 Urinary retention Diseases 0.000 description 1
• 208000026723 Urinary tract disease Diseases 0.000 description 1
• 241001660687 Xantho Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 229940035674 anesthetics Drugs 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 230000001142 anti-diarrhea Effects 0.000 description 1
• 230000002686 anti-diuretic effect Effects 0.000 description 1
• 230000001139 anti-pruritic effect Effects 0.000 description 1
• 230000002932 anti-schizophrenic effect Effects 0.000 description 1
• 239000000043 antiallergic agent Substances 0.000 description 1
• 229940124346 antiarthritic agent Drugs 0.000 description 1
• 239000003793 antidiarrheal agent Substances 0.000 description 1
• 229940124538 antidiuretic agent Drugs 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940125684 antimigraine agent Drugs 0.000 description 1
• 239000002282 antimigraine agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003908 antipruritic agent Substances 0.000 description 1
• 239000003435 antirheumatic agent Substances 0.000 description 1
• 239000002830 appetite depressant Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
• 150000005840 aryl radicals Chemical class 0.000 description 1
• 125000005228 aryl sulfonate group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000005605 benzo group Chemical group 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 208000014679 binge eating disease Diseases 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 208000024330 bloating Diseases 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• 201000007637 bowel dysfunction Diseases 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 150000001715 carbamic acids Chemical class 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 150000004653 carbonic acids Chemical class 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 150000003841 chloride salts Chemical class 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
• 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125797 compound 12 Drugs 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 231100000867 compulsive behavior Toxicity 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 230000002920 convulsive effect Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 229950002213 cyclazocine Drugs 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000005724 cycloalkenylene group Chemical group 0.000 description 1
• 125000002993 cycloalkylene group Chemical group 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 239000011928 denatured alcohol Substances 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000001784 detoxification Methods 0.000 description 1
• 229960001985 dextromethorphan Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• PHBAAFDKJNNRNJ-UHFFFAOYSA-N dimethoxymethoxy(dimethoxy)methane Chemical compound COC(OC)OC(OC)OC PHBAAFDKJNNRNJ-UHFFFAOYSA-N 0.000 description 1
• PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
• 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 230000030136 gastric emptying Effects 0.000 description 1
• 208000001288 gastroparesis Diseases 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000003193 general anesthetic agent Substances 0.000 description 1
• 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 150000008282 halocarbons Chemical class 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
• 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
• 150000002391 heterocyclic compounds Chemical class 0.000 description 1
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
• 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 229960001410 hydromorphone Drugs 0.000 description 1
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 230000035863 hyperlocomotion Effects 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 239000002198 insoluble material Substances 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 230000009191 jumping Effects 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 229910052622 kaolinite Inorganic materials 0.000 description 1
• 206010023461 kleptomania Diseases 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 229940040129 luteinizing hormone Drugs 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229940126601 medicinal product Drugs 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical group NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 1
• 229940087646 methanolamine Drugs 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• QADHFBHNTDGUJQ-UHFFFAOYSA-N n-bromo-2-phenylethanamine Chemical compound BrNCCC1=CC=CC=C1 QADHFBHNTDGUJQ-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000003887 narcotic antagonist Substances 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 229960005118 oxymorphone Drugs 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 230000005371 pilomotor reflex Effects 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229960003975 potassium Drugs 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 230000001141 propulsive effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000003586 protic polar solvent Substances 0.000 description 1
• 208000005333 pulmonary edema Diseases 0.000 description 1
• 210000001747 pupil Anatomy 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000029865 regulation of blood pressure Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 208000024584 respiratory abnormality Diseases 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 230000009329 sexual behaviour Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 210000005070 sphincter Anatomy 0.000 description 1
• 210000004514 sphincter of oddi Anatomy 0.000 description 1
• 238000000528 statistical test Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 239000011593 sulfur Chemical group 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 231100000886 tinnitus Toxicity 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
• 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 239000012873 virucide Substances 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1
• 235000014692 zinc oxide Nutrition 0.000 description 1